Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 1/20 | 0.43 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.43 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.38 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4386435 | 1.00 | CACNA1G (0.43) | CACNA1GCACNA1HCACNA1IALDH1A1MEN1 | |
| SCHEMBL5668410 | 0.83 | LTA4H (0.48) | CACNA1GCACNA1HCACNA1IMEN1KMT2A | |
| SCHEMBL4395355 | 0.83 | ALDH1A1 (0.43) | ALDH1A1MEN1POLBKMT2AHCRTR1 | |
| SCHEMBL4383724 | 0.83 | ALDH1A1 (0.43) | ALDH1A1MEN1POLBKMT2AHCRTR1 | |
| SCHEMBL4392406 | 0.83 | ALDH1A1 (0.43) | ALDH1A1MEN1POLBKMT2AHCRTR1 | |
| SCHEMBL2172285 | 0.82 | CACNA1G (0.45) | CACNA1GCACNA1HCACNA1IALDH1A1MEN1 | |
| SCHEMBL2171264 | 0.81 | NPC1 (0.55) | CACNA1GCACNA1HCACNA1IALDH1A1MEN1 | |
| SCHEMBL4388997 | 0.81 | CACNA1G (0.46) | CACNA1GCACNA1HCACNA1IPOLBKMT2A | |
| SCHEMBL5668902 | 0.80 | CACNA1G (0.44) | CACNA1GCACNA1HCACNA1IALDH1A1MEN1 | |
| SCHEMBL2171492 | 0.80 | TRPV1 (0.56) | CACNA1GCACNA1HCACNA1IMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186905-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2009-07-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186905-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | ALK, BCL3, MCL1 | CACNA1G 4004/4885CACNA1H 4347/4885CACNA1I 4036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.